Publicacions - IR Sant Pau

Cercar

01/11/2022 Pharyngocutaneous fistula in irradiated patients: systematic review and our experience

Casasayas, M, Sansa, A, Garcia-Lorenzo, J, Venegas, MD, Quer, M, Leon, X. Pharyngocutaneous fistula in irradiated patients: systematic review and our experience. JOURNAL OF LARYNGOLOGY AND OTOLOGY. 2022; 136(11)DOI:10.1017/S0022215121004370. PMID:35791885. IF:1.700(Q3/7D).

01/11/2022 Prognostic capacity of the transcriptional expression of lactate dehydrogenase A in patients with head and neck squamous cell carcinoma

Bague, S, Leon, X, Terra, X, Lejeune, M, Camacho, M, Aviles-Jurado, FX. Prognostic capacity of the transcriptional expression of lactate dehydrogenase A in patients with head and neck squamous cell carcinoma. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK. 2022; 44(11)DOI:10.1002/hed.27161. PMID:36207788. IF:2.900(Q1/2D).

01/09/2022 Usefulness of endonasal flaps and grafts in skull base surgery. Consensus document

Moreno-Luna R., Mariño Sánchez F., Kaen A., Gras Cabrerizo J.R., Mata Castro N., González García J., Villacampa Aubá J.M., Cárdenas Ruiz-Valdepeñas E., Monjas Cánovas I., del Cuvillo Bernal A., García Piñero A., Maza Solano J.M., Fernández de Liesa R., Sánchez-Gómez S., Alobid I.. Usefulness of endonasal flaps and grafts in skull base surgery. Consensus document. Acta Otorrinolaringologica Espanola. 2022; 73(5)DOI:10.1016/j.otorri.2021.02.005. PMID:34330369. IF:(Q/D).

01/08/2022 Concordance of p16(INK4a) and E6*I mRNA among HPV-DNA-Positive Oropharyngeal, Laryngeal, and Oral Cavity Carcinomas from the ICO International Study

Mena, M, Wang, X, Tous, S, Quiros, B, Clavero, O, Alejo, M, Morey, F, Taberna, M, Vintro, XL, Rubio, BL, Alos, L, Mehanna, H, Quint, W, Pawlita, M, Tommasino, M, Pavon, MA, Munoz, N, De Sanjose, S, Bosch, FX, Alemany, L. Concordance of p16(INK4a) and E6*I mRNA among HPV-DNA-Positive Oropharyngeal, Laryngeal, and Oral Cavity Carcinomas from the ICO International Study. Cancers. 2022; 14(15)DOI:10.3390/cancers14153787. PMID:35954451. IF:5.200(Q2/3D).

01/06/2022 The Selective Role of Open and Endoscopic Approaches for Sinonasal Malignant Tumours

Lopez, F, Shah, JP, Beitler, JJ, Snyderman, CH, Lund, V, Piazza, C, Makitie, AA, Guntinas-Lichius, O, Rodrigo, JP, Kowalski, LP, Quer, M, Shaha, A, Homma, A, Sanabria, A, Ferrarotto, R, Lee, AWM, Lee, VHF, Rinaldo, A, Ferlito, A. The Selective Role of Open and Endoscopic Approaches for Sinonasal Malignant Tumours. ADVANCES IN THERAPY. 2022; 39(6)DOI:10.1007/s12325-022-02080-x. PMID:35352310. IF:3.800(Q2/4D).

01/05/2022 Semaphorin-3F/Neuropilin-2 Transcriptional Expression as a Predictive Biomarker of Occult Lymph Node Metastases in HNSCC

Meler-Claramonte, C, Aviles-Jurado, FX, Vilaseca, I, Terra, X, Bragado, P, Fuster, G, Vintro, XL, Camacho, M. Semaphorin-3F/Neuropilin-2 Transcriptional Expression as a Predictive Biomarker of Occult Lymph Node Metastases in HNSCC. Cancers. 2022; 14(9)DOI:10.3390/cancers14092259. PMID:35565388. IF:5.200(Q2/3D).

01/05/2022 Self-assembling protein nanocarrier for selective delivery of cytotoxic polypeptides to CXCR4(+) head and neck squamous cell carcinoma tumors

Rioja-Blanco E., Arroyo-Solera I., Álamo P., Casanova I., Gallardo A., Unzueta U., Serna N., Sánchez-García L., Quer M., Villaverde A., Vázquez E., Mangues R., Alba-Castellón L., León X.. Self-assembling protein nanocarrier for selective delivery of cytotoxic polypeptides to CXCR4(+) head and neck squamous cell carcinoma tumors. Acta Pharmaceutica Sinica B. 2022; 12(5)DOI:10.1016/j.apsb.2021.09.030. PMID:35646535. IF:14.500(Q1/1D).

01/04/2022 A Novel CXCR4-Targeted Diphtheria Toxin Nanoparticle Inhibits Invasion and Metastatic Dissemination in a Head and Neck Squamous Cell Carcinoma Mouse Model

Rioja-Blanco, E, Gallardo, A, Arroyo-Solera, I, Alamo, P, Casanova, I, Unzueta, U, Serna, N, Sanchez-Garcia, L, Quer, M, Villaverde, A, Vazquez, E, Leon, X, Alba-Castellon, L, Mangues, R. A Novel CXCR4-Targeted Diphtheria Toxin Nanoparticle Inhibits Invasion and Metastatic Dissemination in a Head and Neck Squamous Cell Carcinoma Mouse Model. Pharmaceutics. 2022; 14(4)DOI:10.3390/pharmaceutics14040887. PMID:35456719. IF:5.400(Q1/2D).

04/02/2022 CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma

Rioja-Blanco, E, Arroyo-Solera, I, Alamo, P, Casanova, I, Gallardo, A, Unzueta, U, Serna, N, Sanchez-Garcia, L, Quer, M, Villaverde, A, Vazquez, E, Leon, X, Alba-Castellon, L, Mangues, R. CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2022; 41(1)DOI:10.1186/s13046-022-02267-8. PMID:35120582. IF:11.300(Q1/1D).

01/01/2022 Sinonasal mucosal melanomas: defining profiles for better survival outcomes

Rojas-Lechuga, MJ, Gras-Cabrerizo, JR, Aviles-Jurado, FX, Malvehy, J, Arance, AM, Castillo, P, Barreiro, A, Podlipnik, S, Lopez-Chacon, M, Alobid, I, Sprekelsen, MB, Puig, S, Langdon, C. Sinonasal mucosal melanomas: defining profiles for better survival outcomes. RHINOLOGY. 2022; 60(5)DOI:10.4193/Rhin21.251. PMID:36184882. IF:7.200(Q1/1D).

01/11/2021 Differential characteristics of patients with squamous cell carcinoma of the head and neck according to gender

Leon, X, Garcia, J, Lopez, M, Holgado, A, Llansana, A, Quer, M. Differential characteristics of patients with squamous cell carcinoma of the head and neck according to gender. Acta Otorrinolaringologica Espanola. 2021; 72(6)DOI:10.1016/j.otorri.2020.08.009. PMID:33618830. IF:(Q/D).

01/09/2021 Risk of contagion of SARS-CoV-2 among otorhinolaryngologists in Spain during the "Two waves"

Martin-Villares, C, Bernal-Sprekelsen, M, Molina-Ramirez, CP, Bartolome-Benito, M, Orus, C, Escamilla Carpintero, Yolanda. Risk of contagion of SARS-CoV-2 among otorhinolaryngologists in Spain during the "Two waves". EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY. 2021; 278(9)DOI:10.1007/s00405-020-06582-8. PMID:33464400. IF:3.236(Q2/3D).

01/11/2025 Prognostic value of pretreatment peripheral blood biomarkers in patients with head and neck squamous cell carcinoma treated with chemo/bioradiotherapy

Sansa, A, Vásquez, R, Valero, C, Vázquez, C, Holgado, A, Gayà, J, Rubio, D, León, X. Prognostic value of pretreatment peripheral blood biomarkers in patients with head and neck squamous cell carcinoma treated with chemo/bioradiotherapy. Clinical & Translational Oncology. 2025; 27(11)DOI:10.1007/s12094-025-03897-y. PMID:40323571. IF:2.500(Q3/6D).

01/10/2025 Neuropilin-2 upregulation by stromal TGFß1 induces lung disseminated tumor cells dormancy escape and promotes metastasis outgrowth

Recalde-Percaz, L, de la Guia-lopez,, Linzoain-Agos, P, Noguera-Castells, A, Rodrigo-Faus, M, Jauregui, P, Lopez-Plana, A, Fernández-Nogueira, P, Iniesta-González, M, Cueto-Remacha, M, Manzano, S, Alonso, R, Moragas, N, Baquero, C, Palao, N, Dalla, F, Avilés-Jurado, FX, Vilaseca,, León-Vintró, X, Camacho, M, Fuster, G, Alcaraz, J, Aguirre-Ghiso, J, Gascón, P, Porras, A, Gutiérrez-Uzquiza, A, Carbó, N, Bragado, P. Neuropilin-2 upregulation by stromal TGFß1 induces lung disseminated tumor cells dormancy escape and promotes metastasis outgrowth. NEOPLASIA. 2025; 68DOI:10.1016/j.neo.2025.101220. PMID:40848614. IF:7.700(Q1/2D).

01/05/2025 Association of human papillomavirus infection with the occurrence of second neoplasms and their prognostic impact in patients with oropharyngeal carcinoma

Gayà, J, Rubio, D, Valero, C, Vázquez-López, C, Holgado, A, Quer, M, León, X. Association of human papillomavirus infection with the occurrence of second neoplasms and their prognostic impact in patients with oropharyngeal carcinoma. Acta Otorrinolaringologica Espanola. 2025; 76(3)DOI:10.1016/j.otorri.2025.512237. PMID:40127862. IF:(Q/D).

01/04/2025 Woake's Syndrome Abscessed in Adults: Case Report

Holgado, A, Casasayas, M, Llansana, A, Gras, JR. Woake's Syndrome Abscessed in Adults: Case Report. Indian Journal of Otolaryngology and Head & Neck Surgery. 2025; 77(4)DOI:10.1007/s12070-024-05285-4. PMID:40226287. IF:0.054(Q4/10D).

09/03/2025 Transcriptional Expression of SLC2A3 and SDHA Predicts the Risk of Local Tumor Recurrence in Patients with Head and Neck Squamous Cell Carcinomas Treated Primarily with Radiotherapy or Chemoradiotherapy

Camacho, M, Bagué, S, Valero, C, Holgadó, A, Lopez-Vilaro, L, Terra, X, Avilés-Jurado, FX, León, X. Transcriptional Expression of SLC2A3 and SDHA Predicts the Risk of Local Tumor Recurrence in Patients with Head and Neck Squamous Cell Carcinomas Treated Primarily with Radiotherapy or Chemoradiotherapy. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025; 26(6)DOI:10.3390/ijms26062451. PMID:40141095. IF:4.900(Q1/3D).

01/02/2025 PATH classification: a proposal for patients with HNSCC treated with salvage surgery

Llansana, A, Porcuna, DV, Vasquez, R, Parellada, A, Valero, C, Holgado, A, León, X. PATH classification: a proposal for patients with HNSCC treated with salvage surgery. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY. 2025; 282(2)DOI:10.1007/s00405-024-08961-x. PMID:39312000. IF:2.200(Q1/3D).

01/01/2025 Predictive capacity for local disease control of neogenin-1 (NEO1) transcriptional expression in patients with head and neck squamous cell carcinoma

Leon, X, Valero, C, Fuster, G, Bragado, P, Camacho, M, Aviles-Jurado, FX. Predictive capacity for local disease control of neogenin-1 (NEO1) transcriptional expression in patients with head and neck squamous cell carcinoma. Clinical & Translational Oncology. 2025; 27(1)DOI:10.1007/s12094-024-03535-z. PMID:38898351. IF:2.500(Q3/6D).

01/01/2025 Endoscopic Vidian neurectomy for treating postcoital unilateral hydrorhinorrhea: A case report and literature review

Massegur, H, Carrera, A, Gras-Cabrerizo, JR, Tubbs, RS, Reina, F. Endoscopic Vidian neurectomy for treating postcoital unilateral hydrorhinorrhea: A case report and literature review. International Journal Of Surgery Case Reports. 2025; 126DOI:10.1016/j.ijscr.2024.110749. PMID:39708722. IF:(Q/D).

01/12/2024 Transcriptional expression of SLC16A7 as a biomarker of occult lymph node metastases in patients with head and neck squamous cell carcinoma

Camacho, M, Vazquez-López, C, Valero, C, Holgado, A, Terra, X, Avilés-Jurado, FX, León, X. Transcriptional expression of SLC16A7 as a biomarker of occult lymph node metastases in patients with head and neck squamous cell carcinoma. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY. 2024; 281(12)DOI:10.1007/s00405-024-08882-9. PMID:39215860. IF:2.200(Q1/3D).

01/11/2024 The current situation of tutoring in specialised training in otorhinolaryngology-head and neck surgery in Spain. Where are we? Where do we want to go?

Canduela, PDD, Jurado, FXA, Beltrán, JD, Ruiz, CM, Gadea, AS, López, F. The current situation of tutoring in specialised training in otorhinolaryngology-head and neck surgery in Spain. Where are we? Where do we want to go?. Acta Otorrinolaringologica Espanola. 2024; 75(6)DOI:10.1016/j.otorri.2024.03.002. PMID:. IF:(Q/D).

01/09/2024 HPV-associated multiphenotypic sinonasal carcinoma. Tumour with indolent behaviour? A case-control study

Ballús, DP, López, L, Bagué, S, Gonzalez, A, Holgado, A, Gras, JR, Szafranska, J. HPV-associated multiphenotypic sinonasal carcinoma. Tumour with indolent behaviour? A case-control study. VIRCHOWS ARCHIV. 2024; 485DOI:. PMID:. IF:3.100(Q2/3D).

01/09/2024 Sinonasal hamarthomas: a rare entity with a challenging diagnosis - how an accurate diagnosis impacts clinical and therapeutic management

Vilaró, LL, Prat, A, Piñol, D, Catasús, L, Rosell, SB, Casasayas, M, Cabrerizo, JRG, Szafranska, J. Sinonasal hamarthomas: a rare entity with a challenging diagnosis - how an accurate diagnosis impacts clinical and therapeutic management. VIRCHOWS ARCHIV. 2024; 485DOI:. PMID:. IF:3.100(Q2/3D).

01/06/2024 Lacrimal duct Surgery: Different Techniques and Long-Term Postoperative Results

Casasayas, M, Massegur-Solench, H, Martel-Marín, M, Kolanczak, KA, Holgado, A, Gras-Cabrerizo, JR. Lacrimal duct Surgery: Different Techniques and Long-Term Postoperative Results. Indian Journal of Otolaryngology and Head & Neck Surgery. 2024; DOI:10.1007/s12070-024-04670-3. PMID:39376430. IF:0.054(Q4/10D).

01/05/2024 Current opinion on laryngeal electromyography

Ramírez-Ruiz, RD, Quintillá, M, Sandoval, M, León, L, Costa, JM, Quer, M. Current opinion on laryngeal electromyography. Acta Otorrinolaringologica Espanola. 2024; 75(3)DOI:10.1016/j.otorri.2023.07.001. PMID:37913988. IF:(Q/D).

01/04/2024 Host-related indexes in head and neck cancer

Valero, C, León, X, Quer, M. Host-related indexes in head and neck cancer. Current Opinion in Otolaryngology & Head and Neck Surgery. 2024; 32(2)DOI:10.1097/MOO.0000000000000954. PMID:38116851. IF:2.000(Q2/3D).

01/03/2024 Prognostic capacity of PIV (pan-immune-inflammation value) in patients with head and neck squamous cell carcinoma

Sansa, A, Valero, C, Pujol, A, Sauter, B, Gayà, J, Quer, M, León, X. Prognostic capacity of PIV (pan-immune-inflammation value) in patients with head and neck squamous cell carcinoma. Acta Otorrinolaringologica Espanola. 2024; 75(2)DOI:10.1016/j.otorri.2023.07.005. PMID:38220048. IF:(Q/D).

01/03/2024 Surgical treatment of 186 sinonasal inverted papillomas and analysis of the immunohistochemical and molecular features associated with recurrences*

Gras-Cabrerizo, JR, Martel-Martin, M, Casasayas-Plass, M, Kolanczak, K, Lopez-Vilaró, L, Szafranska, J, Massegur-Solench, H, León-Vintró, X. Surgical treatment of 186 sinonasal inverted papillomas and analysis of the immunohistochemical and molecular features associated with recurrences*. AMERICAN JOURNAL OF OTOLARYNGOLOGY. 2024; 45(2)DOI:10.1016/j.amjoto.2023.104129. PMID:38070378. IF:1.700(Q2/4D).

10/02/2024 Clinical practice guideline on the management of vestibular schwannoma.

Lassaletta L, Acle Cervera L, Altuna X, Amilibia Cabeza E, Arístegui Ruiz M, Batuecas Caletrio Á, Benítez Del Rosario J, Cabanillas Farpón R, Costales Marcos M, Escada P, Espinosa-Sánchez JM, García Leal R, Gavilán J, Gómez Martínez J, González-Aguado R, Martinez-Glez V, Guerra Jiménez G, Harguindey Antolí-Candela A, Hernández García BJ, Orús Dotú C, Polo López R, Manrique M, Martín Sanz E, Martínez Álvarez R, Martínez H, Martínez-Martínez M, Rey-Martinez J, Ropero Romero F, Santa Cruz Ruiz S, Vallejo LÁ, Soto Varela A, Varela-Nieto I, Morales Puebla JM. Clinical practice guideline on the management of vestibular schwannoma.. Acta Otorrinolaringologica Espanola. 2024; 75(2)DOI:10.1016/j.otoeng.2023.10.005. PMID:38346489. IF:(Q/D).

26/08/2022 Usefulness of endonasal flaps and grafts in skull base surgery. Consensus document.

Moreno-Luna R, Mariño Sánchez F, Kaen A, Gras Cabrerizo JR, Mata Castro N, González García J, Villacampa Aubá JM, Cárdenas Ruiz-Valdepeñas E, Monjas Cánovas I, Del Cuvillo Bernal A, García Piñero A, Maza Solano JM, Fernández de Liesa R, Sánchez-Gómez S, Alobid I. Usefulness of endonasal flaps and grafts in skull base surgery. Consensus document.. Acta Otorrinolaringologica Espanola. 2022; 73(5)DOI:10.1016/j.otoeng.2021.02.004. PMID:36031110. IF:(Q/D).

01/06/2022 A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper

Zozaya, N, Villaseca, J, Abdalla, F, Calleja, MA, Diez-Martin, JL, Estevez, J, Garcia-Sanz, R, Martinez-Lopez, J, Sierra, J, Vera, R, Hidalgo-Vega, A. A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper. Clinical & Translational Oncology. 2022; 24(6)DOI:10.1007/s12094-021-02757-9. PMID:34997475. IF:3.400(Q3/6D).

12/05/2022 Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies

Burger, JA, Robak, T, Demirkan, F, Bairey, O, Moreno, C, Simpson, D, Munir, T, Stevens, DA, Dai, S, Cheung, LWK, Kwei, K, Lal, I, Hsu, EM, Kipps, TJ, Tedeschi, A. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. LEUKEMIA & LYMPHOMA. 2022; 63(6)DOI:10.1080/10428194.2021.2020779. PMID:35014928. IF:2.600(Q3/7D).

21/03/2022 Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma

Halwani, AS, Panizo, C, Isufi, I, Herrera, AF, Okada, CY, Cull, EH, Kis, B, Chaves, JM, Bartlett, NL, Ai, WY, De La Cruz-Merino, L, Bryan, LJ, Houot, R, Linton, K, Briones, J, Chau, I, von Keudell, GR, Lu, HL, Yakovich, A, Chen, M, Ter Meulen, JH, Yurasov, S, Hsu, FJ, Flowers, CR. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. LEUKEMIA & LYMPHOMA. 2022; 63(4)DOI:10.1080/10428194.2021.2010057. PMID:34865586. IF:2.600(Q3/7D).

01/03/2022 Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT

Hernandez-Boluda, JC, Pereira, A, Zinger, N, Gras, L, Martino, R, Paneesha, S, Finke, J, Chinea, A, Rambaldi, A, Robin, M, Saccardi, R, Natale, A, Snowden, JA, Tsirigotis, P, Vallejo, C, Wulf, G, Xicoy, B, Russo, D, Maertens, J, Daguindau, E, Lenhoff, S, Hayden, P, Czerw, T, McLornan, DP, Yakoub-Agha, I. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. BONE MARROW TRANSPLANTATION. 2022; 57(3)DOI:10.1038/s41409-021-01553-x. PMID:35066569. IF:4.800(Q1/2D).

23/02/2022 Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients

Pinana, JL, Vazquez, L, Martino, R, de la Camara, R, Sureda, A, Rodriguez-Veiga, R, Garrido, A, Sierra, J, Ribera, JM, Torrent, A, Mateos, MV, de la Rubia, J, Tormo, M, Diez-Campelo, M, Garcia-Gutierrez, V, Alvarez-Larran, A, Sancho, JM, MartinGarcia-Sancho, A, Yanez, L, Simon, JAP, Barba, P, Abrisqueta, P, Alvarez-Twose, I, Bonanad, S, Lecumberri, R, Ruiz-Camps, I, Navarro, D, Hernandez-Rivas, JA, Cedillo, A, Garcia-Sanz, R, Bosch, F. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. LEUKEMIA & LYMPHOMA. 2022; 63(3)DOI:10.1080/10428194.2021.1992619. PMID:34668835. IF:2.600(Q3/7D).

01/02/2022 Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation

Martino, R, Garcia-Cadenas, I, Esquirol, A. Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation. BONE MARROW TRANSPLANTATION. 2022; 57(2)DOI:10.1038/s41409-021-01507-3. PMID:34711914. IF:4.800(Q1/2D).

01/02/2022 Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma

Dlouhy, I, Karube, K, Enjuanes, A, Salaverria, I, Nadeu, F, Ramis-Zaldivar, JE, Valero, JG, Rivas-Delgado, A, Magnano, L, Martin-Garcia, D, Perez-Galan, P, Clot, G, Rovira, J, Jares, P, Balague, O, Gine, E, Mozas, P, Briones, J, Sancho, JM, Salar, A, Mercadal, S, Alcoceba, M, Valera, A, Campo, E, Lopez-Guillermo, A. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 196(3)DOI:10.1111/bjh.17858. PMID:34632572. IF:6.500(Q1/3D).

01/02/2022 Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3-PBX1 treated with measurable residual disease-oriented protocols

Ribera, J, Granada, I, Morgades, M, Gonzalez, T, Ciudad, J, Such, E, Calasanz, MJ, Mercadal, S, Coll, R, Gonzalez-Campos, J, Tormo, M, Garcia-Cadenas, I, Gil, C, Cervera, M, Barba, P, Costa, D, Ayala, R, Bermudez, A, Orfao, A, Ribera, JM. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3-PBX1 treated with measurable residual disease-oriented protocols. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 196(3)DOI:10.1111/bjh.17844. PMID:34549416. IF:6.500(Q1/3D).

01/02/2022 Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials

Allan, JN, Shanafelt, T, Wiestner, A, Moreno, C, O'Brien, SM, Li, JL, Krigsfeld, G, Dean, JP, Ahn, IE. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 196(4)DOI:10.1111/bjh.17984. PMID:34865212. IF:6.500(Q1/3D).

02/01/2022 A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results

Lopez-Guillermo, A, Canales, MA, Dlouhy, I, Mercadal, S, Briones, J, Garcia-Sancho, AM, Sancho, JM, Moraleda, JM, Terol, MJ, Salar, A, Palomera, L, Gardella, S, Jarque, I, Ferrer, S, Bargay, J, Lopez, A, Panizo, C, Muntanola, A, Montalban, C, Conde, E, Hernandez, MT, Soler, A, Marco, JAG, Deben, G, Marin, J, Tomas, JF. A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results. LEUKEMIA & LYMPHOMA. 2022; 63(1)DOI:10.1080/10428194.2021.1971216. PMID:34459702. IF:2.600(Q3/7D).

01/01/2022 SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group

Pinana, JL, Lopez-Corral, L, Martino, R, Montoro, J, Vazquez, L, Perez, A, Martin-Martin, G, Facal-Malvar, A, Ferrer, E, Pascual, MJ, Sanz-Linares, G, Gago, B, Sanchez-Salinas, A, Villalon, L, Conesa-Garcia, V, Olave, MT, Lopez-Jimenez, J, Marcos-Corrales, S, Garcia-Blazquez, M, Garcia-Gutierrez, V, Hernandez-Rivas, JA, Saus, A, Espigado, I, Alonso, C, Hernani, R, Solano, C, Ferrer-Lores, B, Guerreiro, M, Ruiz-Garcia, M, Munoz-Bellido, JL, Navarro, D, Cedillo, A, Sureda, A. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. AMERICAN JOURNAL OF HEMATOLOGY. 2022; 97(1)DOI:10.1002/ajh.26385. PMID:34695229. IF:12.800(Q1/1D).

01/01/2022 The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations

Kanda, J, Hayashi, H, Ruggeri, A, Kimura, F, Volt, F, Takahashi, S, Kako, S, Tozatto-Maio, K, Yanada, M, Sanz, G, Uchida, N, Angelucci, E, Kato, S, Mohty, M, Forcade, E, Tanaka, M, Sierra, J, Ohta, T, Saccardi, R, Fukuda, T, Ichinohe, T, Kimura, T, Rocha, V, Okamoto, S, Nagler, A, Atsuta, Y, Gluckman, E. The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. BONE MARROW TRANSPLANTATION. 2022; 57(1)DOI:10.1038/s41409-021-01479-4. PMID:34635798. IF:4.800(Q1/2D).

01/01/2022 Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results

Rucker, FG, Du, L, Luck, TJ, Benner, A, Krzykalla, J, Gathmann, I, Voso, MT, Amadori, S, Prior, TW, Brandwein, JM, Appelbaum, FR, Medeiros, BC, Tallman, MS, Savoie, L, Sierra, J, Pallaud, C, Sanz, MA, Jansen, JH, Niederwieser, D, Fischer, T, Ehninger, G, Heuser, M, Ganser, A, Bullinger, L, Larson, RA, Bloomfield, CD, Stone, RM, Dohner, H, Thiede, C, Dohner, K. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. LEUKEMIA. 2022; 36(1)DOI:10.1038/s41375-021-01323-0. PMID:34316017. IF:11.400(Q1/1D).

01/01/2022 A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model

Pallares, V, Unzueta, U, Falgas, A, Avino, A, Nunez, Y, Garcia-Leon, A, Sanchez-Garcia, L, Serna, N, Gallardo, A, Alba-Castellon, L, Alamo, P, Sierra, J, Cedo, L, Eritja, R, Villaverde, A, Vazquez, E, Casanova, I, Mangues, R. A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model. BIOMATERIALS. 2022; 280DOI:10.1016/j.biomaterials.2021.121258. PMID:34847435. IF:14.000(Q1/1D).

30/12/2021 MRD in CLL: some answers, many questions

Moreno, C, Mora, A. MRD in CLL: some answers, many questions. BLOOD. 2021; 138(26)DOI:10.1182/blood.2021013435. PMID:34967869. IF:25.669(Q1/1D).

01/12/2021 An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

Jimenez, AMJ, De Lima, M, Komanduri, KV, Wang, TP, Zhang, MJ, Chen, KR, Abdel-Azim, H, Abid, MB, Aljurf, M, Alkhateeb, H, Assal, A, Bacher, U, Baron, F, Battiwalla, M, Beitinjaneh, A, Bejanyan, N, Bhatt, VR, Byrne, M, Cahn, JY, Cairo, M, Castillo, P, Copelan, E, DeFilipp, Z, Perez, MAD, Elsawy, M, Gale, RP, George, B, Grunwald, MR, Hildebrandt, GC, Hogan, WJ, Kanakry, CG, Kansagra, A, Kharfan-Dabaja, MA, Khera, N, Krem, MM, Lazaryan, A, Maakaron, J, Martino, R, McGuirk, J, Michelis, FV, Milone, G, Mishra, A, Murthy, HS, Mussetti, A, Nathan, S, Nishihori, T, Olsson, RF, Palmisiano, N, Patel, S, Saad, A, Seo, S, Sharma, A, Solh, M, Verdonck, LF, Wirk, B, Yared, JA, Litzow, M, Kebriaei, P, Hourigan, CS, Saber, W, Weisdorf, D. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. BONE MARROW TRANSPLANTATION. 2021; 56(12)DOI:10.1038/s41409-021-01450-3. PMID:34584240. IF:5.174(Q2/3D).

01/12/2021 Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma

Granell, M, Senin, A, Barata, A, Cibeira, MT, Gironella, M, Lopez-Pardo, J, Motllo, C, Garcia-Guinon, A, Ben-Azaiz, R, Abella, E, Soler, A, Canet, M, Marti, JM, Martino, R, Sierra, J, de Larrea, CF, Oriol, A, Rosinol, L. Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma. BONE MARROW TRANSPLANTATION. 2021; 56(12)DOI:10.1038/s41409-021-01429-0. PMID:34404917. IF:5.174(Q2/3D).

01/12/2021 Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study

Diefenbach, C, Kahl, BS, McMillan, A, Briones, J, Banerjee, L, Cordoba, R, Miall, F, Burke, JM, Hirata, J, Jiang, YW, Paulson, JN, Chang, YM, Musick, L, Abrisqueta, P. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. Lancet Haematology. 2021; 8(12)DOI:10.1016/S2352-3026(21)00311-2. PMID:34826412. IF:30.153(Q1/1D).

01/11/2021 The road to chemotherapy-free treatment in chronic lymphocytic leukaemia

Albiol, N, Arguello-Tomas, M, Moreno, C. The road to chemotherapy-free treatment in chronic lymphocytic leukaemia. CURRENT OPINION IN ONCOLOGY. 2021; 33(6)DOI:10.1097/CCO.0000000000000791. PMID:34474439. IF:3.915(Q3/6D).

15/10/2021 Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively

Moreno, C, Munoz, C, Terol, MJ, Hernandez-Rivas, JA, Villanueva, M. Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2021; 40(1)DOI:10.1186/s13046-021-02115-1. PMID:34654437. IF:12.658(Q1/1D).

01/10/2021 The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies

Einsele, H, Briones, J, Ciceri, F, Cadenas, IG, Falkenburg, F, Bolanos, N, Heemskerk, HMM, Houot, R, Hudecek, M, Locatelli, F, Morgan, K, Morris, EC, O'Dwyer, M, Sierra, JG, van den Brink, M, van de Loosdrecht, AA. The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies. Hemasphere. 2021; 5(10)DOI:10.1097/HS9.0000000000000642. PMID:34522844. IF:8.300(Q1/2D).

01/10/2021 Adverse prognostic impact of complex karyotype (>= 3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)

Genesca, E, Morgades, M, Gonzalez-Gil, C, Fuster-Tormo, F, Haferlach, C, Meggendorfer, M, Montesinos, P, Barba, P, Gil, C, Coll, R, Moreno, MJ, Martinez-Carballeira, D, Garcia-Cadenas, I, Vives, S, Ribera, J, Gonzalez-Campos, J, Diaz-Beya, M, Mercadal, S, Artola, MT, Cladera, A, Tormo, M, Bermudez, A, Vall-llovera, F, Martinez-Sanchez, P, Amigo, ML, Monsalvo, S, Novo, A, Cervera, M, Garcia-Guinon, A, Ciudad, J, Cervera, J, Hernandez-Rivas, JM, Granada, I, Haferlach, T, Orfao, A, Sole, F, Ribera, JM. Adverse prognostic impact of complex karyotype (>= 3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). LEUKEMIA RESEARCH. 2021; 109DOI:10.1016/j.leukres.2021.106612. PMID:34139642. IF:3.715(Q3/6D).

01/10/2021 Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain

Ribera, JM, Morgades, M, Coll, R, Barba, P, Lopez-Lorenzo, JL, Montesinos, P, Foncillas, MA, Cabrero, M, Gomez-Centurion, I, Morales, MD, Varela, MR, Herrera, P, Garcia-Cadenas, I, Calbacho, M, Torrent, A, Maluquer, C, Calabuig, M, Garcia-Guinon, A, Bautista, G, Llorente, L, Gil, C, Artola, MT, Gonzalez-Campos, J, Fernandez-Moreno, A, Barez, A, Gimenez-Perez, T, Bergua, J, Sanchez-Sanchez, MJ, Mateos, MC, Pinana, JL. Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain. Clinical Lymphoma Myeloma & Leukemia. 2021; 21(10)DOI:10.1016/j.clml.2021.06.024. PMID:34376375. IF:2.822(Q3/8D).

01/10/2021 Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials

Ribera, JM, Morgades, M, Genesca, E, Chapchap, EC, Montesinos, P, Acuna-Cruz, E, Gil, C, Garcia-Cadenas, I, Barba, P, Gonzalez-Campos, J, de Llano, MPQ, Torrent, A, Ribera, J, Granada, I, Bernal, T, Diaz-Beya, M, Amigo, ML, Coll, R, Tormo, M, Vall-llovera, F, Gomez-Centurion, I, Sanchez-Sanchez, MJ, Soria, B, Cladera, A, Artola, MT, Garcia-Guinon, A, Gimenez-Conca, A, Amador, ML, Martinez-Sanchez, P, Algarra, JL, Vidal, MJ, Alonso, N, Maluquer, C, Llorente, L, Garcia-Boyero, R, Ciudad, J, Feliu, E, Orfao, A. Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials. HEMATOLOGICAL ONCOLOGY. 2021; 39(4)DOI:10.1002/hon.2910. PMID:34405901. IF:4.850(Q2/5D).

01/10/2021 COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey

Ljungman, P, de la Camara, R, Mikulska, M, Tridello, G, Aguado, B, Al Zahrani, M, Apperley, J, Berceanu, A, Bofarull, RM, Calbacho, M, Ciceri, F, Lopez-Corral, L, Crippa, C, Fox, ML, Grassi, A, Jimenez, MJ, Demir, SK, Kwon, M, Llamas, CV, Lorenzo, JLL, Mielke, S, Orchard, K, Porras, RP, Vallisa, D, Xhaard, A, Knelange, NS, Cedillo, A, Kroger, N, Pinana, JL, Styczynski, J. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. LEUKEMIA. 2021; 35(10)DOI:10.1038/s41375-021-01302-5. PMID:34079042. IF:12.897(Q1/1D).

01/10/2021 Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide

Esquirol, A, Pascual, MJ, Kwon, M, Perez, A, Parody, R, Ferra, C, Cadenas, IG, Herruzo, B, Dorado, N, Hernani, R, Sanchez-Ortega, I, Torrent, A, Sierra, J, Martino, R. Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. BONE MARROW TRANSPLANTATION. 2021; 56(10)DOI:10.1038/s41409-021-01328-4. PMID:34059802. IF:5.174(Q2/3D).

30/09/2021 CEBPA bZip mutations: just a single shot

Sierra, J, Nomdedeu, JF. CEBPA bZip mutations: just a single shot. BLOOD. 2021; 138(13)DOI:10.1182/blood.2021011263. PMID:34591099. IF:25.669(Q1/1D).

01/09/2021 The EHA Research Roadmap: Malignant Myeloid Diseases

Dohner, H, Malcovati, L, Ossenkoppele, GJ, Hochhaus, A, Vannucchi, AM, Bullinger, L, Cervantes, F, Craddock, C, de Witte, T, Dohner, K, Dombret, H, Fenaux, P, Geissler, J, Germing, U, Guilhot, F, Harrison, C, Hellstrom-Lindberg, E, Passamonti, F, Sierra, J, Skoda, R, Wierzbowska, A. The EHA Research Roadmap: Malignant Myeloid Diseases. Hemasphere. 2021; 5(9)DOI:10.1097/HS9.0000000000000635. PMID:34476345. IF:8.300(Q1/2D).

01/09/2021 Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

Larson, RA, Mandrekar, SJ, Huebner, LJ, Sanford, B, Laumann, K, Geyer, S, Bloomfield, CD, Thiede, C, Prior, TW, Dohner, K, Marcucci, G, Voso, MT, Klisovic, RB, Galinsky, I, Wei, AH, Sierra, J, Sanz, MA, Brandwein, JM, de Witte, T, Niederwieser, D, Appelbaum, FR, Medeiros, BC, Tallman, MS, Krauter, J, Schlenk, RF, Ganser, A, Serve, H, Ehninger, G, Amadori, S, Gathmann, I, Dohner, H, Stone, RM. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. LEUKEMIA. 2021; 35(9)DOI:10.1038/s41375-021-01179-4. PMID:33654204. IF:12.897(Q1/1D).